Published in Am J Psychiatry on June 01, 2014
D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD | NCT00356278
Estrogen and extinction of fear memories: implications for posttraumatic stress disorder treatment. Biol Psychiatry (2015) 1.17
The impact of benzodiazepine management in the randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy. Am J Psychiatry (2014) 1.09
Possible negative effects of extinction learning on outcomes for patients receiving exposure therapy. Am J Psychiatry (2014) 1.06
Virtual reality exposure-based therapy for the treatment of post-traumatic stress disorder: a review of its efficacy, the adequacy of the treatment protocol, and its acceptability. Neuropsychiatr Dis Treat (2015) 1.00
An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials. Biol Psychiatry (2015) 0.92
Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors. Front Psychiatry (2014) 0.91
Baroreflex dysfunction and augmented sympathetic nerve responses during mental stress in veterans with post-traumatic stress disorder. J Physiol (2017) 0.88
Diagnostic Biomarkers for Posttraumatic Stress Disorder: Promising Horizons from Translational Neuroscience Research. Biol Psychiatry (2015) 0.88
PTSD: from neurobiology to pharmacological treatments. Eur J Psychotraumatol (2016) 0.87
Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats. Behav Brain Res (2015) 0.84
Virtual Reality-Enhanced Extinction of Phobias and Post-Traumatic Stress. Neurotherapeutics (2017) 0.82
Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder. Expert Rev Neurother (2014) 0.82
Cognitive disruptions in stress-related psychiatric disorders: A role for corticotropin releasing factor (CRF). Horm Behav (2015) 0.82
GABA and NMDA receptors in CRF neurons have opposing effects in fear acquisition and anxiety in central amygdala vs. bed nucleus of the stria terminalis. Horm Behav (2015) 0.80
Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions. Biol Psychiatry (2015) 0.79
Physiological reactivity to nonideographic virtual reality stimuli in veterans with and without PTSD. Brain Behav (2014) 0.77
The impact of PTSD treatment on the cortisol awakening response. Depress Anxiety (2014) 0.77
D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial. J Clin Psychiatry (2015) 0.77
Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemp Clin Trials (2015) 0.76
An investigation of outcome expectancies as a predictor of treatment response for combat veterans with PTSD: comparison of clinician, self-report, and biological measures. Depress Anxiety (2015) 0.76
Genome-wide gene-based analysis suggests an association between Neuroligin 1 (NLGN1) and post-traumatic stress disorder. Transl Psychiatry (2016) 0.76
Pharmacologic augmentation of extinction learning during exposure therapy for PTSD. Am J Psychiatry (2014) 0.75
Catecholamine responses to virtual combat: implications for post-traumatic stress and dimensions of functioning. Front Psychol (2015) 0.75
More than Just a Game? Combat-Themed Gaming Among Recent Veterans with Posttraumatic Stress Disorder. Games Health J (2015) 0.75
The Use of Virtual Reality Technology in the Treatment of Anxiety and Other Psychiatric Disorders. Harv Rev Psychiatry (2017) 0.75
The effect of D-cycloserine on social anxiety treatment using a behavioral outcome measure and a post-session administration strategy. Behav Anal (Wash D C) (2016) 0.75
Pilot Study of a Telehealth-Delivered Medication-Augmented Exposure Therapy Protocol for PTSD. J Nerv Ment Dis (2016) 0.75
D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis. PLoS One (2017) 0.75
Response to Granoff. Am J Psychiatry (2014) 0.75
Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy. Behav Res Ther (2016) 0.75
Response to Smith. Am J Psychiatry (2014) 0.75
Psychological and psychobiological responses to immediate early intervention in the emergency department: Case report of one-session exposure therapy for the prevention of PTSD. Pract Innov (Wash D C) (2017) 0.75
Review of Virtual Reality Treatment in Psychiatry: Evidence Versus Current Diffusion and Use. Curr Psychiatry Rep (2017) 0.75
Dexamethasone facilitates fear extinction and safety discrimination in PTSD: A placebo-controlled, double-blind study. Psychoneuroendocrinology (2017) 0.75
Repeated trauma exposure does not impair distress reduction during imaginal exposure for posttraumatic stress disorder. Depress Anxiety (2016) 0.75
GABA Concentrations in the Anterior Cingulate Cortex Are Associated with Fear Network Function and Fear Recovery in Humans. Front Hum Neurosci (2017) 0.75
Emotional Modulation of Learning and Memory: Pharmacological Implications. Pharmacol Rev (2017) 0.75
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 65.11
The development of a Clinician-Administered PTSD Scale. J Trauma Stress (1995) 22.71
Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med (2004) 16.53
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry (2004) 5.26
Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci (2002) 4.52
Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry (2008) 3.63
D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry (2007) 3.03
A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry (2012) 2.12
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry (2009) 2.09
A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry (2008) 2.03
Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol Psychiatry (2010) 2.02
Effectiveness of national implementation of prolonged exposure therapy in Veterans Affairs care. JAMA Psychiatry (2013) 1.98
D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry (2013) 1.94
D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. Behav Neurosci (2004) 1.75
A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res (2012) 1.50
A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behav Res Ther (2006) 1.44
State-dependent fear extinction with two benzodiazepine tranquilizers. Behav Neurosci (1990) 1.42
Psychophysiological assessment: clinical applications for PTSD. J Affect Disord (2000) 1.41
D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry (2013) 1.26
D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology (2013) 1.18
Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther (2010) 1.18
Virtual reality exposure therapy using a virtual Iraq: case report. J Trauma Stress (2008) 1.10
Virtual reality exposure therapy for post-traumatic stress disorder and other anxiety disorders. Curr Psychiatry Rep (2010) 1.09
D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res (2013) 1.09
Valproic acid but not D-cycloserine facilitates sleep-dependent offline learning of extinction and habituation of conditioned fear in humans. Neuropharmacology (2012) 0.99
Alterations in stress reactivity after long-term treatment with paroxetine in women with posttraumatic stress disorder. Ann N Y Acad Sci (2006) 0.98
Patient and facility characteristics associated with benzodiazepine prescribing for veterans with PTSD. Psychiatr Serv (2013) 0.92
Virtual reality exposure therapy for active duty soldiers. J Clin Psychol (2008) 0.91
Pretreatment cortisol levels predict posttreatment outcomes among older adults with depression in cognitive behavioral therapy. Psychiatry Res (2013) 0.88
Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA (2008) 6.60
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry (2004) 5.26
Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature (2011) 4.94
Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci (2012) 4.71
Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry (2008) 4.65
Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ (2012) 4.64
Behavioral and neural analysis of extinction. Neuron (2002) 4.53
Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci (2002) 4.52
Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol (2003) 4.08
Trauma exposure and stress-related disorders in inner city primary care patients. Gen Hosp Psychiatry (2009) 3.88
Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J Med Chem (2005) 3.32
Different mechanisms of fear extinction dependent on length of time since fear acquisition. Learn Mem (2006) 3.30
HIV-1 infection in high risk men who have sex with men in Mombasa, Kenya. AIDS (2007) 3.22
Applying learning principles to the treatment of post-trauma reactions. Ann N Y Acad Sci (2003) 3.05
Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83
Brain-derived neurotrophic factor and tyrosine kinase receptor B involvement in amygdala-dependent fear conditioning. J Neurosci (2004) 2.73
Characterization of Bouveret's syndrome: a comprehensive review of 128 cases. Am J Gastroenterol (2006) 2.58
A significant decline in the American domination of research in gastroenterology with increasing globalization from 1980 to 2005: an analysis of American authorship among 8,251 articles. Am J Gastroenterol (2008) 2.53
Emotion, motivation, and the brain: reflex foundations in animal and human research. Prog Brain Res (2006) 2.52
Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis (2006) 2.44
Impaired fear inhibition is a biomarker of PTSD but not depression. Depress Anxiety (2010) 2.27
Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning. Am J Psychiatry (2010) 2.25
How the neurocircuitry and genetics of fear inhibition may inform our understanding of PTSD. Am J Psychiatry (2010) 2.24
Pain symptomatology and pain medication use in civilian PTSD. Pain (2011) 2.16
Posttraumatic stress disorder among African Americans in an inner city mental health clinic. Psychiatr Serv (2005) 2.13
Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder. Trends Neurosci (2011) 2.12
Regulation of synaptic plasticity genes during consolidation of fear conditioning. J Neurosci (2002) 2.10
Amygdala BDNF signaling is required for consolidation but not encoding of extinction. Nat Neurosci (2006) 2.10
Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies. Arch Gen Psychiatry (2011) 2.09
The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron (2011) 2.02
Estrogen levels are associated with extinction deficits in women with posttraumatic stress disorder. Biol Psychiatry (2012) 2.02
Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol Psychiatry (2010) 2.02
Role of the extended amygdala in short-duration versus sustained fear: a tribute to Dr. Lennart Heimer. Brain Struct Funct (2008) 1.97
Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology (2005) 1.89
The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav (2002) 1.87
Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder. Proc Natl Acad Sci U S A (2013) 1.86
Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther (2004) 1.83
Differential immune system DNA methylation and cytokine regulation in post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet (2011) 1.83
Risk and resilience: genetic and environmental influences on development of the stress response. Depress Anxiety (2009) 1.79
Conditioned fear extinction and reinstatement in a human fear-potentiated startle paradigm. Learn Mem (2006) 1.78
Posttraumatic stress disorder may be associated with impaired fear inhibition: relation to symptom severity. Psychiatry Res (2009) 1.76
Amygdala-dependent fear is regulated by Oprl1 in mice and humans with PTSD. Sci Transl Med (2013) 1.74
Prelimbic cortical BDNF is required for memory of learned fear but not extinction or innate fear. Proc Natl Acad Sci U S A (2010) 1.72
Implications of memory modulation for post-traumatic stress and fear disorders. Nat Neurosci (2013) 1.72
Regulation of gephyrin and GABAA receptor binding within the amygdala after fear acquisition and extinction. J Neurosci (2005) 1.72
Conditioned pharmacotherapeutic effects: a preliminary study. Psychosom Med (2009) 1.68
Alterations in diurnal cortisol rhythm and acoustic startle response in nonhuman primates with adverse rearing. Biol Psychiatry (2005) 1.65
Association of CRP genetic variation and CRP level with elevated PTSD symptoms and physiological responses in a civilian population with high levels of trauma. Am J Psychiatry (2014) 1.60
Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS (2014) 1.58
Validity of prototype diagnosis for mood and anxiety disorders. JAMA Psychiatry (2013) 1.56
An empirically derived taxonomy for personality diagnosis: bridging science and practice in conceptualizing personality. Am J Psychiatry (2012) 1.55
Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency. Pediatr Transplant (2007) 1.54
More than military sexual trauma: interpersonal violence, PTSD, and mental health in women veterans. Res Nurs Health (2011) 1.54
The renin-angiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms. J Clin Psychiatry (2012) 1.54
Differential regulation of brain-derived neurotrophic factor transcripts during the consolidation of fear learning. Learn Mem (2004) 1.53
Impaired safety signal learning may be a biomarker of PTSD. Neuropharmacology (2011) 1.52
Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology (2010) 1.51
Fear potentiation and fear inhibition in a human fear-potentiated startle paradigm. Biol Psychiatry (2005) 1.49
Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. Eur Urol (2009) 1.49
Timing of extinction relative to acquisition: a parametric analysis of fear extinction in humans. Behav Neurosci (2008) 1.45
Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev (2008) 1.44
Training-induced changes in the expression of GABAA-associated genes in the amygdala after the acquisition and extinction of Pavlovian fear. Eur J Neurosci (2007) 1.43